Does S. boulardii Speed Recovery From Acute Diarrhea in Young Children?
Yes, by about a day and a half. In this trial, diarrhea lasted 4.7 days on average with S. boulardii, compared with 6.2 days on placebo. Diarrhea lasting more than 7 days hit 3 of 44 children (7%) on S. boulardii and 12 of 44 (27%) on placebo. That is about 1 fewer case of prolonged diarrhea for every 5 children treated. It was a double-blind, placebo-controlled trial in Argentina of 100 outpatients aged 3 to 24 months, with S. boulardii or placebo given for 6 days alongside oral rehydration solution.
Dr. Kumar’s Take
This RCT tested a clear, common group: children under 2 years with mild to moderate acute infective diarrhea, treated as outpatients. S. boulardii added to ORS helped them recover about 1.5 days sooner, reduced stool frequency, and lowered the risk of prolonged diarrhea. For early intervention in young children, this is evidence you want in your toolbox.
Key Takeaways
- 100 children aged 3 to 24 months with mild‐to‐moderate diarrhea of less than 7 days duration.
- S. boulardii given for 6 days alongside oral rehydration solution (ORS).
- Mean diarrhea duration dropped from ~6.16 days (placebo) to ~4.70 days with S. boulardii.
- Stool frequency on the 4th day was significantly lower in treatment arm.
- Diarrhea lasting more than 7 days: 3 of 44 children (7%) with S. boulardii vs 12 of 44 (27%) with placebo, a 75% relative reduction.
Actionable Tip
For infants and toddlers under 2 with new acute infectious diarrhea, ask your pediatrician about adding S. boulardii early, ideally within 48 hours, alongside ORS. In this trial it was given for 6 days. A common pediatric dose is 250 mg twice daily. In this trial, children on S. boulardii recovered faster on average and had fewer stools by day 4.
Study Summary
These researchers conducted a randomized, double‑blind, placebo‑controlled trial in Argentina among outpatients. Children under 2 years with mild/moderate diarrhea were randomized to receive S. boulardii vs placebo, in addition to standard ORS care, for 6 days. Outcomes included duration of diarrhea, stool frequency, and risk of prolonged diarrhea.
Study Design
- Population: Children aged 3 to 24 months, ambulatory, mild to moderate acute diarrhea (onset <7 days)
- Intervention: S. boulardii plus ORS for 6 days
- Control: Placebo plus ORS
- Outcomes:
- Duration of diarrhea
- Stool frequency on day 4
- Proportion with diarrhea lasting over 7 days
- Analysis: Follow‑up to allow measuring both immediate outcome (diarrhea course) and short‑term risk of prolonged illness
Results
- Duration: ~4.70 days with S. boulardii vs ~6.16 days with placebo
- Stool frequency (day 4): ~2.5 stools/day in S. boulardii group vs ~3.5 in placebo
- Risk of diarrhea >7 days: 3/44 (7%) in treatment vs 12/44 (27%) in placebo (RR 0.25)
Biological Rationale
- In this trial, children who started within 48 hours had fewer stools on days 4 and 7. Early use may help by acting before the infection does more damage.
- S. boulardii may help by modulating intestinal secretion and inflammatory response, reducing stool volume and improving fluid absorption.
- It may also help restore microbial balance more quickly. This trial did not measure these mechanisms.
Strengths & Limits
Strengths:
- Very clear patient population (young children, mild/moderate disease) which is clinically common.
- Blinded, placebo‑controlled design.
- Multiple outcome measures (duration, stool count, prolonged illness) giving triangulation.
Limitations:
- Single country site (Argentina); generalizability may vary.
- Only mild/moderate cases; severe diarrhea may behave differently.
- Dose fixed; studies comparing different doses/durations less common.
Related Studies and Research
- Saccharomyces boulardii in the prevention of antibiotic‑associated diarrhea in children: RCT
- SB + Amoxicillin‑Clavulanate Effects on Gut Microbiota (RCT)
- High‑Dose Vancomycin + SB for Recurrent C. difficile
- Saccharomyces boulardii Explained: Podcast Episode
FAQ
Would this benefit hold in children older than 2 years?
Likely yes, though this study focused under‑2s. Other studies in older children also show benefit, but effect sizes may vary.
What if treatment starts late (after 48 hours)?
Starting early mattered. Children who began S. boulardii within 48 hours of the diarrhea starting had fewer stools on days 4 and 7 than those who began later. The authors concluded it works better when given in the first 48 hours.
Is this safe for home treatment vs hospital?
Yes, this was done in outpatient/ambulatory settings.
Bottom Line
In young children under 2, S. boulardii as an adjunct to ORS shortens acute diarrhea by about 1.5 days, lowers stool frequency and reduces risk of prolonged illness (>7 days). Early intervention matters.
